Adaptive Biotechnologies Corp

ADPTUnited States

40 filed reports · 358 financial concepts · 12 earnings calls

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$277M

FY2025 · to Dec 31, 2025

up +54.8% vs $179M

10-K

Net income

-$59.5M

FY2025 · to Dec 31, 2025

a year earlier: -$159M

10-K

Operating income

-$57.1M

FY2025 · to Dec 31, 2025

a year earlier: -$163M

10-K

Latest quarter

Revenue

$83.9M

Q3 FY2026 · to Sep 30, 2026

down −10.7% vs $94M

10-Q

Net income

$2.88M

Q3 FY2026 · to Sep 30, 2026

down −69.9% vs $9.55M

10-Q

Operating income

-$457K

Q3 FY2026 · to Sep 30, 2026

a year earlier: $10.3M

10-Q

Filed reports

40 reports · Jun 2019 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 18 guidance figures, 9 earnings-release figures, 30 commentary passages.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR233,614Jun 2019 to Sep 2026
Current · 8-KSEC EDGAR1027Mar 2021 to Sep 2026
Annual · 10-KSEC EDGAR72,941Dec 2019 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q38-K2026-09-302026-11-049Open
FY2026 Q310-Q2026-09-302026-11-04336Open
FY2026 Q210-Q2026-06-302026-08-04228Open
FY2026 Q110-Q2026-03-312026-05-05218Open
FY202510-K2025-12-312026-02-26787Open
FY2025 Q310-Q2025-09-302025-11-05153Open
FY2025 Q210-Q2025-06-302025-08-05149Open
FY2025 Q110-Q2025-03-312025-05-01166Open
FY202410-K2024-12-312025-03-03406Open
FY2024 Q48-K2024-12-312025-02-112Open
FY2024 Q310-Q2024-09-302024-11-07157Open
FY2024 Q210-Q2024-06-302024-08-01156Open

Financial data

358 concepts · 6,582 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial338 concepts · 6,135 facts · Dec 2017 to Sep 2026

  • Allocated share based compensation expense44 · Dec 2017 to Sep 2026
  • Amortization of intangible assets44 · Dec 2017 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations44 · Dec 2017 to Sep 2026
  • Comprehensive income net of tax44 · Dec 2017 to Sep 2026
  • Cost of goods and services sold (US GAAP)44 · Dec 2017 to Sep 2026
  • Costs and expenses44 · Dec 2017 to Sep 2026
  • General and administrative expense (US GAAP)44 · Dec 2017 to Sep 2026
  • Interest and other income44 · Dec 2017 to Sep 2026
  • Net income loss44 · Dec 2017 to Sep 2026
  • Operating income loss44 · Dec 2017 to Sep 2026
  • Other comprehensive income loss net of tax portion attributable to parent44 · Dec 2017 to Sep 2026
  • Other comprehensive income unrealized holding gain loss on securities arising during period net of tax44 · Dec 2017 to Sep 2026
  • Research and development expense44 · Dec 2017 to Sep 2026
  • Revenue44 · Dec 2017 to Sep 2026
  • Selling and marketing expense (US GAAP)44 · Dec 2017 to Sep 2026
  • Stockholders equity (US GAAP)44 · Dec 2017 to Sep 2026
  • Stock issued during period value stock options exercised44 · Dec 2017 to Sep 2026
  • Accretion amortization of discounts and premiums investments42 · Dec 2017 to Sep 2026
  • Capital expenditures incurred but not yet paid42 · Dec 2017 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect42 · Dec 2017 to Sep 2026
  • Depreciation42 · Dec 2017 to Sep 2026
  • Increase decrease in accounts payable and accrued liabilities42 · Dec 2017 to Sep 2026
  • Increase decrease in accounts receivable42 · Dec 2017 to Sep 2026
  • Increase decrease in contract with customer liability42 · Dec 2017 to Sep 2026

Segment14 concepts · 325 facts · Dec 2022 to Sep 2026

  • Operating Segments63 · Dec 2022 to Sep 2026
  • Allocated share based compensation expense46 · Dec 2022 to Sep 2026
  • Revenue38 · Dec 2022 to Sep 2026
  • Depreciation and amortization34 · Dec 2022 to Sep 2026
  • Research and development expense30 · Dec 2022 to Sep 2026
  • Profit loss16 · Mar 2023 to Sep 2026
  • Cost of goods and services sold (US GAAP)15 · Dec 2022 to Sep 2026
  • General and administrative expense (US GAAP)15 · Dec 2022 to Sep 2026
  • Selling and marketing expense (US GAAP)15 · Dec 2022 to Sep 2026
  • Restructuring charges14 · Mar 2024 to Sep 2026
  • Costs and expenses12 · Mar 2023 to Sep 2024
  • Net income loss12 · Mar 2023 to Sep 2024
  • Impairment of long lived assets held for use11 · Mar 2024 to Sep 2026
  • Goodwill4 · Dec 2024 to Dec 2025

Product3 concepts · 100 facts · Dec 2017 to Mar 2026

  • Revenue77 · Dec 2017 to Dec 2025
  • Contract with customer liability revenue recognized13 · Sep 2019 to Dec 2021
  • Sequencing Revenue10 · Dec 2019 to Mar 2026

Guidance2 concepts · 18 facts · May 2021 to Feb 2025

  • Revenue Guidance16 · May 2021 to Aug 2023
  • Free Cash Flow Guidance2 · Feb 2025

KPI1 concept · 4 facts · Sep 2025 to Sep 2026

  • Net income (loss) attributable to Adaptive Biotechnologies Corporation4 · Sep 2025 to Sep 2026

Segments

425 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments5 members · 325 facts

  • Mrd Business177 · Dec 2022 to Sep 2026
  • Immune Medicine Business132 · Dec 2022 to Sep 2026
  • Mrd Business Segment And Immune Medicine Business12 · Dec 2023 to Mar 2026
  • Immune medicine business2 · Dec 2024 to Dec 2025
  • Mrd business segment2 · Dec 2024 to Dec 2025

Product or service7 members · 100 facts

  • Sequencing Revenue44 · Dec 2017 to Mar 2026
  • Development Revenue21 · Dec 2017 to Dec 2021
  • Immune Medicine Service Revenue16 · Dec 2022 to Dec 2025
  • Development Support Revenue5 · Dec 2017 to Dec 2021
  • Sequencing Revenue From Coverage Policy5 · Mar 2019 to Dec 2019
  • Sequencing Revenue From Test Deliver5 · Mar 2019 to Dec 2019
  • Development Revenue Regulatory Milestones4 · Dec 2018 to Dec 2021

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Earnings-release commentary11 claims from 1 report · Sep 2026
  • Management discussion (MD&A) commentary19 claims from 1 report · Sep 2026
  • Risk-factor changes67 claims from 5 reports · Dec 2020 to Dec 2024
  • Risk factors454 risks from 6 annual reports · 2019 to 2024

Earnings calls

12 calls · Feb 2024 to Nov 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q32026-11-04
  • FY2026 Q22026-07-29
  • FY2026 Q12026-05-05
  • FY2025 Q42026-02-05
  • FY2025 Q32025-11-06
  • FY2025 Q22025-08-06
  • FY2025 Q12025-05-01
  • FY2024 Q42025-02-11
  • FY2024 Q32024-11-07
  • FY2024 Q22024-08-01
  • FY2024 Q12024-05-07
  • FY2023 Q42024-02-14

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Adaptive Biotechnologies Corp (ADPT) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

Adaptive Biotechnologies Corp (ADPT): FY2025 revenue $277M · FactIQ